Back to search results

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

Abroad (travel likely)RecruitingPHASE3

Conditions

Hidradenitis Suppurativa

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hs0006 50175, Phoenix, Arizona, United States

  • Hs0006 50708, Roseville, California, United States

  • Hs0006 50684, Sacramento, California, United States

  • Hs0006 50707, Washington D.C., District of Columbia, United States

  • Hs0006 50199, Miami, Florida, United States

  • Hs0006 50712, Bowling Green, Kentucky, United States

  • Hs0006 50178, Clarkston, Michigan, United States

  • Hs0006 50710, Fort Gratiot, Michigan, United States

  • Hs0006 50711, Troy, Michigan, United States

  • Hs0006 50706, Chapel Hill, North Carolina, United States

  • Hs0006 50202, Fairborn, Ohio, United States

  • Hs0006 50201, Arlington, Texas, United States

  • Hs0006 40326, Berlin, Germany

  • Hs0006 40747, Mainz, Germany

  • Hs0006 40625, Lodz, Poland

  • Hs0006 40761, Warsaw, Poland

  • Hs0006 40095, Wroclaw, Poland

  • Hs0006 40845, Wroclaw, Poland

Study leads

  • UCB Cares

    Study Director

    001 844 599 2273

View source on ClinicalTrials.gov(opens in a new tab)